Metastatic Triple-Negative Breast Cancer

Abstract Purpose of Review Triple-negative breast cancer (TNBC) is a heterogeneous disease group with known aggressive phenotype and poor prognosis. To date, it remains challenging given its lack oncogenic targets as seen in hormone receptor + or HER2 cancers, limited efficacy traditional chemotherapy. This article review the latest key literature management metastatic TNBC offers glimpse ongoing drug development. Recent Findings paradigm-shifting trials led to incorporation immune checkpoint inhibitors chemotherapy frontline setting for positive PDL1-expression. Novel antibody–drug conjugates new (Trop2, HER2) now offer additional treatment options TNBC. Summary There have been significant strides understanding tumor-immune microenvironment molecular vulnerabilities As evolves rapidly, novel combination therapies therapeutic strategies will continue improve patient outcomes.